ImmunityBio
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2014-01-01
- Employees
- 628
- Market Cap
- $2.9B
- Website
- http://www.immunitybio.com
- Introduction
ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong ...
Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-01-23
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 126
- Registration Number
- NCT01514188
- Locations
- 🇺🇦
Vinnytsya Regional Clinical Oncologic Dispensary, Surgical Department, Vinnytsya, Ukraine
🇮🇳Jehangir Clinical Development Centre Pvt Ltd, Pune, Maharashtra, India
🇮🇳Christian Medical College, Vellore, Tami Nadu, India
Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2011-04-19
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01337505
- Locations
- 🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States
QUILT-3.018: Neukoplast™ (NK-92) for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia
- First Posted Date
- 2009-05-13
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT00900809
- Locations
- 🇺🇸
UPMC Cancer Center - Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
© Copyright 2024. All Rights Reserved by MedPath